RxDoctor Payments Data

Jesse Guadiz, MD

Family Medicine · Rialto, CANPI 1558317933

Payments from drug & device makers

$582in general payments, 2019–2025

Across 37 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$88
  • Merck$80
  • Amarin Pharma, Inc.$66
  • Abbott$62
  • Novartis$61
  • GSK$47
  • plus $178 from 8 others

What the payments were for

  • Food & beverage$56397%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$582 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$24,715
Medicare patients
71
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate200$221,119
TrulicityDulaglutide127$146,538
JardianceEmpagliflozin148$145,249
FarxigaDapagliflozin Propanediol92$80,237
OzempicSemaglutide72$74,184
EliquisApixaban66$60,827
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog72$52,530
XareltoRivaroxaban50$42,895
SteglatroErtugliflozin Pidolate61$37,924
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog100$32,174
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$29,888
RybelsusSemaglutide28$26,199
LinzessLinaclotide36$25,884
Lantus SolostarInsulin Glargine,hum.Rec.Anlog138$19,043
TradjentaLinagliptin20$16,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Steglatro$80$259,043261 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Synjardy Xr$25$185,319207 claims
Lilly USA, LLCTrulicity$21$146,538127 claims
Novo NordiskOzempic, Rybelsus$32$100,384100 claims
AstraZenecaFarxiga, Pulmicort Flexhaler$88$84,239109 claims
PfizerEliquis$31$60,82766 claims
Johnson & JohnsonXarelto$14$42,89550 claims
GSKTrelegy Ellipta, Incruse Ellipta$47$34,29446 claims
NovartisEntresto$61$16,26816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Rialto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →